Cumberland Pharmaceuticals, Inc. 是一家专业制药公司,专注于品牌处方药品的收购、开发和商业化。公司总部位于田纳西州纳什维尔,目前拥有91名全职员工。公司于2009年8月11日上市。该公司致力于品牌处方药品的收购、开发和商业化。其品牌组合包括:Acetadote(乙酰半胱氨酸)注射剂,用于对乙酰氨基酚中毒的治疗;Caldolor(布洛芬)注射剂,用于治疗疼痛和发烧;Kristalose(乳果糖)口服溶液,一种处方泻药,用于治疗便秘;Sancuso(格拉司琼)透皮贴剂,用于预防接受某些类型化疗的患者的恶心和呕吐;Vaprisol(考尼伐坦)注射剂,用于提高因等容或高容性低钠血症住院患者的血清钠水平;以及Vibativ(特拉万星)注射剂,用于治疗某些严重的细菌感染,包括医院获得性和呼吸机相关性细菌性肺炎,以及复杂的皮肤及皮肤结构感染。
Based on comprehensive analyst evaluations, we have synthesized critical insights from expert assessments to outline a cautious outlook for CPIX. Analysts note deteriorating fundamentals and challenging market sentiment, indicating potential downside risks in the near term. Following this expert analysis, we adopt a bearish stance on this stock. Our conclusion: CPIX is a Sell candidate.
CPIX stock price ended at $3.86 on 星期二, after rising 0.26%
On the latest trading day Feb 10, 2026, the stock price of CPIX rose by 0.26%, climbing from $3.82 to $3.86. During the session, the stock saw a volatility of 6.47%, with prices oscillating between a daily low of $3.71 and a high of $3.95. Notably, trading volume dropped by 32.9K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 126.4K shares were traded, equating to a market value of approximately $57.7M.